4.2 Article

Cold Blood Versus Crystalloid Cardioplegia for Myocardial Protection in Adult Cardiac Surgery: A Meta-analysis of Randomized Controlled Studies

Journal

JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
Volume 28, Issue 3, Pages 674-681

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.jvca.2013.06.005

Keywords

Cold blood cardioplegia; crystalloid cardioplegia; meta-analysis; randomized controlled trials

Ask authors/readers for more resources

The purpose of this article was to systematically review randomized controlled trials in which cold blood cardioplegia was compared with cold crystalloid cardioplegia for cardiac surgery. Design: Correlation studies were searched independently in the EMBASE, MEDLINE and Cochrane library databases. The primary endpoints of interest were spontaneous sinus rhythm (SSR) after declamping, perioperative myocardial infarction (MI) and mortality (within 30 days). Setting: A hospital. Participants: Randomized controlled trials. Intervention: A meta-analysis of 12 studies. Measurements and Main Results: The 12 included trials recruited a total of 2866 participants; 1357 patients received cold crystalloid cardioplegia, and 1509 patients received cold blood cardioplegia. The pooled analysis showed no significant difference favoring either cold crystalloid cardioplegia or cold blood cardioplegia in terms of spontaneous sinus rhythm (SSR) after declamping (789/1028 [76.75%] v 773/ 1025 [75.41%], relative risk (RR) = 0.92 [0.76, 1.13], p = 0.43 with 6 studies included), mortality (within 30 days) (20/1335 [1.50%] v 24/1469 [1.63%], relative risk (RR) = 1.09 [0.62, 1.91], p = 0.77 with 11 studies included), atrial fibrillation (AF) (329/1043 [31.54%] v365/1040 [35.10%], RR =0.90 [0.80, 1.01], p = 0.08 with 6 studies included) or stroke (45/1114 [4.04%] v 20/1240 [1.61%], RR = 2.18 [0.69, 6.93], p = 0.19 with 4 studies included). The aggregate data showed that the incidence of perioperative myocardial infarction was lower in patients who received cold blood cardioplegia (CB) (32/1310 [2.44%] v 17/1434 [1.19%], RR = 2.30 [1.33, 3.98], p = 0.003 with 11 studies included). Conclusions: Cold blood cardioplegia reduced perioperative myocardial infarction when compared with cold crystalloid cardioplegia. No differences in the overall incidence rates of spontaneous sinus rhythm, mortality (within 30 days), atrial fibrillation or stroke were observed. (C) 2014 Published by Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Multidisciplinary Sciences

Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Xingsheng Hu, Ke Pu, Xuqin Feng, Shimin Wen, Xi Fu, Cuihua Guo, Wenwu He

PLOS ONE (2016)

Article Multidisciplinary Sciences

Is IMRT Superior or Inferior to 3DCRT in Radiotherapy for NSCLC? A Meta-Analysis

Xingsheng Hu, Wenwu He, Shimin Wen, Xuqin Feng, Xi Fu, Yusong Liu, Ke Pu

PLOS ONE (2016)

Article Respiratory System

Gene set enrichment analysis and meta-analysis to identify six key genes regulating and controlling the prognosis of esophageal squamous cell carcinoma

Wenwu He, Linxin Chen, Kun Yuan, Qiuxi Zhou, Lin Peng, Yongtao Han

JOURNAL OF THORACIC DISEASE (2018)

Article Oncology

Gene set enrichment analysis and meta-analysis identified 12 key genes regulating and controlling the prognosis of lung adenocarcinoma

Wenwu He, Liangmin Fu, Qunlun Yan, Qiuxi Zhou, Kun Yuan, Linxin Chen, Yongtao Han

ONCOLOGY LETTERS (2019)

Article Oncology

A five-gene signature to predict the overall survival time of patients with esophageal squamous cell carcinoma

Wenwu He, Qunlun Yan, Liangmin Fu, Yongtao Han

ONCOLOGY LETTERS (2019)

Article Surgery

Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus From the Results of NEOCRTEC5010, a Randomized Multicenter Study

Xuefeng Leng, Wenwu He, Hong Yang, Yuping Chen, Chengchu Zhu, Wentao Fang, Zhentao Yu, Weimin Mao, Jiaqing Xiang, Zhijian Chen, Haihua Yang, Jiaming Wang, Qingsong Pang, Xiao Zheng, Hui Liu, Huanjun Yang, Tao Li, Xu Zhang, Qun Li, Geng Wang, Teng Mao, Xufeng Guo, Ting Lin, Mengzhong Liu, Jianhua Fu, Yongtao Han

Summary: The study found that pathologic lymph node metastasis is a strong poor prognostic factor in esophageal squamous cell carcinoma patients after neoadjuvant chemoradiotherapy. Pathologic complete response does not guarantee a cure, and active surveillance and adjuvant therapy should be considered for these patients.

ANNALS OF SURGERY (2021)

Article Oncology

Genomic characteristics in neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma

Wenwu He, Xuefeng Leng, Kangning Wang, Tiaoqin Mao, Lin Peng, Qiang Fang, Wenguang Xiao, Yongtao Han

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2020)

Article Oncology

Moderately differentiated esophageal squamous cell carcinoma has a poor prognosis after neoadjuvant chemoradiotherapy

Wenwu He, Tianqin Mao, Jiaxin Yan, Xuefeng Leng, Xuyang Deng, Qin Xie, Lin Peng, Qiong Liao, Marco Scarpa, Yongtao Han

Summary: The study revealed that patients with poorly differentiated tumors have a higher pathological complete response rate after NCRT but poorer long-term survival, while patients with moderately differentiated tumors show poor outcomes in both short and long term. Lymph node status after NCRT is a crucial prognostic factor for ESCC treatment.

ANNALS OF TRANSLATIONAL MEDICINE (2021)

Article Oncology

The impact of adjuvant therapy on survival for node-negative esophageal squamous cell carcinoma: a propensity score-matched analysis

Xuyang Deng, Wenwu He, Yingchun Jiang, Sijie Deng, Tianqin Mao, Xuefeng Leng, Qiyu Luo, Kai Zheng, Yongtao Han

Summary: This study found that postoperative adjuvant therapy, especially chemotherapy, can prolong overall survival and disease-free survival in patients with esophageal squamous cell carcinoma (ESCC) who have pathologically node-negative disease. Additionally, T3 stage tumors and <15 lymph node dissections were identified as independent risk factors for overall survival and disease-free survival in pN0 ESCC patients.

ANNALS OF TRANSLATIONAL MEDICINE (2021)

Article Oncology

Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Wenwu He, Xuefeng Leng, Tianqin Mao, Xi Luo, Lingxiao Zhou, Jiaxin Yan, Lin Peng, Qiang Fang, Guangyuan Liu, Xing Wei, Kangning Wang, Chenghao Wang, Sha Zhang, Xudong Zhang, Xudong Shen, Depei Huang, Huan Yi, Ting Bei, Xueke She, Wenguang Xiao, Yongtao Han

Summary: This study focuses on locally advanced resectable esophageal squamous cell carcinoma (ESCC), investigating the safety, feasibility, and efficacy of neoadjuvant toripalimab plus paclitaxel and carboplatin treatment. The results indicate that this combination therapy shows potential as a neoadjuvant treatment for ESCC, with increased CD8(+) T cells and decreased M2-type tumor-associated macrophages in responders. Furthermore, certain molecular signatures were associated with treatment response.

ONCOLOGIST (2022)

Article Oncology

MMS22L Expression as a Predictive Biomarker for the Efficacy of Neoadjuvant Chemoradiotherapy in Oesophageal Squamous Cell Carcinoma

Qiyu Luo, Wenwu He, Tianqin Mao, Xuefeng Leng, Hong Wu, Wen Li, Xuyang Deng, Tingci Zhao, Ming Shi, Chuan Xu, Yongtao Han

Summary: Long-term survival in oesophageal squamous cell carcinoma (ESCC) is closely linked to the pathological response following neoadjuvant chemoradiotherapy (NCRT) and surgery. A study identified 101 genes associated with the efficacy of chemoradiotherapy, with MMS22L gene showing significant correlation with ESCC patient outcomes. Low MMS22L expression is associated with poor response to NCRT, worse survival, lymph node metastasis, and enhanced migration of tumor cells in ESCC.

FRONTIERS IN ONCOLOGY (2021)

Article Immunology

Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study

Wenwu He, Chenghao Wang, Lei Wu, Gang Wan, Baisen Li, Yongtao Han, Haojun Li, Xuefeng Leng, Kunyi Du, Haijun Chen, Qifeng Wang, Lin Peng

Summary: This study explored the safety and efficacy of tislelizumab plus chemotherapy sequential neoadjuvant therapy for non-cCR patients and provided a novel neoadjuvant therapy model that can benefit patients with locally advanced ESCC.

FRONTIERS IN IMMUNOLOGY (2022)

Article Oncology

Alleviation of neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma and its relationship with expression and changes of PD-L1

Ye-Han Zhou, Jia-Yu Li, Jia-Xin Yan, Peng Guo, Wen-Wu He, Yang Liu

Summary: This study compared the effects of neoadjuvant immunochemotherapy (NICT) and neoadjuvant chemoradiotherapy (NCRT) in esophageal squamous cell carcinoma (ESCC), and evaluated the correlation between the expression and changes of PD-L1 and the efficacy of NICT. The results showed that both NICT and NCRT could upregulate the expression of PD-L1, with NCRT having a more significant effect. The preoperative expression levels of PD-L1 were not effective in predicting the degree of pathological response, but high IPS and high IPS downregulation were associated with better response. Some patients with low preoperative expression of PD-L1 could still achieve a good response with NICT.

NEOPLASMA (2022)

Article Medicine, Research & Experimental

Identification of tumor-infiltrating lymphocyte subpopulations correlated with patient prognosis in esophageal squamous cell carcinoma

Lin Peng, Wenwu He, Feng Ye, Yane Song, Xinying Shi, Jiao Zhang, Qingyun Li, Qiang Fang, Wenguang Xiao, Yongtao Han

Summary: By analyzing genetic variations and tumor-infiltrating lymphocytes levels, 488 differentially expressed genes related to esophageal squamous cell carcinoma prognosis were identified. The levels of MDSCs and Th2 cells can serve as biomarkers for assessing the prognosis of patients with ESCC.

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2021)

No Data Available